Understanding the Endocannabinoid System in Autism and Its Implications for Therapeutics

Recent studies suggest abnormal cannabinoid receptor type 2 (CB2) signalling in peripheral blood mononuclear cells (PBMCs) extracted from autistic children, implying the endocannabinoid system could be functionally involved in ASD-mediated immune impairments. Cannabinoid 1 receptors are present on neurons and microglial cells and additional research implicates these receptors in neuronal protection in a way which may represent a therapeutic target in ASDs. Research will be presented.

James Jeffrey Bradstreet

Date/Time:

Fri, 05/23/2014 - 2:00pm - 3:00pm

Room:

CASSATT

Track:

Conference 2014

AutismOne is a private, nonprofit, 501(c)3 organization with its primary mission of helping children and families within the autism spectrum and related conditions. AutismOne is an educational organization, and all lectures, information, and presentations are for informational purposes only. No information on this website nor any AutismOne related event should be construed as medical and/or legal advice or recommendations. We strongly advise that all children needing specific medical or legal advice seek counsel of a duly licensed professional. Every child is unique, and to attempt to address complex medical issues without a trained and experienced expert is akin to a lay person attempting to perform surgery without any training. Doing either would risk serious (and in some cases could have irreversible) consequences.